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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The main objective of this review is to compare the female condom to the male condom as a method of contraception.
B A C K G R O U N D
In response to rapidly growing populations, governments aim to
achieve a balance between the number of individuals and available
resources. Ensuring access to and adequate use of effective con-
traceptive methods (Rabe 1999) slows down population growth.
Access to safe abortion and delivery is also essential in control-
ling population growth and improving reproductive health. About
208 million women become pregnant each year worldwide, 123
million(59%) of which are intended pregnancies leading to a live
birth, a miscarriage or a stillbirth and 85 million(41%) of which
are unintended pregnancies (WHO 2012c). About 41 million of
these unintended pregnancies end in induced abortions and al-
most an equal proportion end in delivery (Ahmed 2012).
India was the first country to establish a national family-planning
program in 1952 (Rabe 1999), and several other countries fol-
lowed this example shortly afterwards. Low educational levels, po-
litical, religious and socio-cultural factors limit the spread of con-
traceptive methods and lead to uncontrolled population growth
(Rabe 1999). An example of political measures to control births is
China, where the number of children a couple is allowed to have is
restricted and India where emphasis is laid on specific family plan-
ning methods like sterilisation (Filshie 1991). However, a contra-
ceptive method must be available before any decisions regarding
it’s use by the public are considered.
With the advent of theHuman Immuno-Defficiency Virus (HIV)
pandemic, the role of condoms became critical in the control of
its spread. It is estimated that there were 3.1 million new HIV
infections in 1999 and 2.6 million new HIV infections in 2009
(UNAIDS 2010). A systematic review found that consistent con-
domuse is effective in reducing sexual transmission ofHIV (Weller
2012). Onlymale and female condoms provide dual protection by
reducing the risk of HIV transmission and preventing unintended
pregnancies (Ahmed 2012). Condoms are therefore essential not
only as a contraceptive method, but also as a means of reducing
the risk of HIV transmission.
Description of the condition
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Each year, about 22 million unsafe abortions take place leading to
an estimated 47 000 pregnancy-related deaths and an additional
5 million women who suffer disability as a result of complications
due to unsafe abortion (WHO 2012c). Adequate family planning
services are necessary in order to reduce the number of unwanted
pregnancies and hence, the number of induced abortions. Despite
availability of several contraceptive methods, several factors influ-
ence the choice of contraceptive use. Recently, the role of emo-
tions in decision making when it comes choice of condom use
has been shown to be significant (Gutnik 2006). Religious and/or
cultural issues also influence the acceptability of various contra-
ceptive methods depending on their advantages and disadvantages
(Rabe 1999).
Several factors influence the success of any program on contra-
ception and the acceptability of each method is a key issue. Some
factors that affect acceptability of a contraceptive method in-
clude(Deniaud 1997):
-The method; the visual aspect of the device, its tolerance and
efficacy,
-The way the method is distributed; cost and accessibility of the
method.
-The users; personal motivations, perception of STI risk, previous
use of device, religious and moral considerations.
-The users’ partner; his/her motivations and co-operation.
-The context; both socio-economic context and type of personal
relationship that exists between the partners in the couple.
Description of the intervention
Condoms belong to the group of male and female barrier contra-
ceptives methods (Filshie 1991), and they are the oldest known
method among these (Rabe 1999). The earliest publication that
describes condoms was in 1564 and they have been used as far
back as the Roman times for preventing STIs (Filshie 1991). There
are two types; the male and the female condom and both consist
of a sheath that is open at one end and closed at the other. The
male and female condom have different designs, adapted to the
anatomy of the male and female reproductive organs respectively.
The FC requires an anchor outside the vagina to prevent invagi-
nation, which is usually a ring or frame, and a mechanism for in-
serting the device and stabilizing it once fitted (Beksinska 2011).
Several types of materials can be used for making condoms like
natural latex, polyurethenes and synthetic rubbers (WHO2012b).
There are a number of adverse effects associated with condom use
like condom-associated erection problems (either during applica-
tion or during intercourse while using a condom) and problems
with the ‘fit’ or ‘feel’ of condoms, including problems related to
the size and shape of the condom, or discomfort or interference
with sensation (Sanders 2012).
How the intervention might work
Condoms serve as a mechanical barrier during sexual intercourse,
that prevent semen from getting into the vagina (Filshie 1991).
They are worn by the male or female partner, prior to the sexual
encounter and must be removed and disposed of correctly in order
to carry out their desired function. Assessment of the protective
properties of condoms must consider their effectiveness, which is
their performance under real conditions, and their efficacy, which
is their performance under ideal conditions (Haddad 2012). Con-
doms can be used along with another contraceptive method. The
double Dutch method is when condoms are used together with
oral contraceptive pills and in this case, they provide increased
protection against unwanted pregnancies (Bromham 1995).
The two main types of male condom failure are breakage and slip-
page (Steiner 1994). Female condom failure is defined as a condom
for which a non clinical breakage, a clinical breakage or a slippage
occurs or is associated withmisdirection or invagination or any ad-
ditional identified failure mode. Nonclinical breakage is defined as
breakage noticed before intercourse or occurring after withdrawal
of the condom from the vagina. Nonclinical breakage is breakage
without potential adverse clinical consequences. Clinical breakage
is defined as breakage during intercourse or withdrawal of the FC
from the vagina. Clinical breakage is breakage with potential ad-
verse clinical consequences. Clinical breakage includes events in
which the outer frame or ring breaks. Total breakage is defined as
breakage at any time before, during or after intercourse. It includes
clinical breakage and non clinical breakage. Slippage is defined as
an FC that slips completely out of the vagina during intercourse.
Misdirection is defined as vaginal penetration whereby the penis
is inserted between the FC and the vaginal wall. Invagination is
defined as part or the entire external component of the FC being
pushed into the vagina during intercourse. Total Clinical Failure
is defined as the number of FCs that clinically break or slip, or are
associated with misdirection or invagination during intercourse
or any additional failure mode(s) identified in the risk assessment
(Beksinska 2007).Condom failure can be affected by a number of
factors including condom age and storage conditions, penis size,
condom fit, use of lubricants, user experience with the condom
type and intensity of coital activity (Haddad 2012). However, the
frequency of occurrence of female condom failures reduces with
user experience (Beksinska 2012).
Why it is important to do this review
TheWorld Health Organisation (WHO) defined a medium-term
strategic plan from 2008-2013 defining the strategic direction to
be taken by member states in order to attain a set of health goals
and provide a monitoring and assessment framework to measure
progress over time. The WHO’s second strategic objective is to
combat HIV/AIDS, tuberculosis andmalaria (WHO2012a). The
strategic objectives number four and six involve improving re-
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productive health and reducing unsafe sex respectively (WHO
2012a). Condoms are key components in improving sexual and
reproductive health and they ensure safer sex for their users. Fe-
male condoms have been available to the public since the early
1990s (WHO2012b, Beksinska 2011) and are now widely used as
an effective method of contraception. A study carried out among
female sex workers found that female condoms gave them more
power and also increased their ability to control their sexual and
reproductive health (Mathenjwa 2012). It is therefore important
to find out if the female condom is comparable to the male con-
dom as a method of contraception.
O B J E C T I V E S
Themain objective of this review is to compare the female condom
to the male condom as a method of contraception.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Condoms can be used for various periods of time, implying that
users have to be followed up for long periods in order to assess
long term effectiveness and side-effects. We intend to include only
randomised controlled trials in this review bearing in mind that
follow-up time of participantsmay not allow for evaluation of long
term benefits and side-effects.
Types of participants
It is possible for a man or woman to have multiple sexual partners.
In this case, condoms can be used for preventing unwanted preg-
nancies and for preventing STIs. A relationship in which the man
or woman has multiple sexual partners introduces several factors
that affect assessment of the effectiveness of the condom due to
individual variations in anatomy and sexual preferences or prac-
tices.
We will focus on data from the female partner and include data on
the male partner if adequate information is available. Our partici-
pants will be healthy women of reproductive age who engage only
in heterosexual vaginal intercourse and who are in a monogamous
relationship.
Types of interventions
We will compare use of the female condom to the male condom
as a contraceptive method.
Condoms are used by a couple during sexual intercourse. The fact
that the man wears the MC and the woman, the FC, represents a
difference in the manner in which the two interventions function.
Effectiveness of each type of condom is therefore influenced by
each individual partner in the couple. However, since both MC
and FC carry out their contraceptive function during intercourse
by protecting the woman from semen exposure, we can consider
them comparable as two interchangeable devices for contracep-
tion.
Types of outcome measures
Primary outcomes
The primary outcomes will be:
- Incidence of pregnancy.
- Incidence of condom failure. Participant-reported condom fail-
ure can be used in estimating the incidence of condom failure. It is
also possible to test the condom for mechanical failure using lab-
oratory tests. Recently, testing for prostate-specific antigen (PSA)
which is a bio-marker of semen exposure has been shown to be a
more objective measure of condom failure (Mauck 2007).We will
therefore include participant-reported and objective measures of
assessment of condom failure in this review.
Secondary outcomes
Wewill report the following outcomes in both themale and female
partners:
- adverse events related to condom use. This includes allergic re-
actions to the lubricant gel found in condoms or to the material
used to manufacture the condoms.
- measures of acceptability, for example, condom-associated erec-
tion problems and problems with fit and feel of the condom.
- incidence of STIs and HIV infection. This refers to any sexually
transmitted infection and HIV transmission reported by the au-
thors.
Search methods for identification of studies
Electronic searches
We will contact the trial search coordinator for the Fertility Regu-
lation Group in order to elaborate a comprehensive search strategy.
We will search the following databases: MEDLINE, EMBASE,
POPLINE, LILACS and CENTRAL (the Cochrane central reg-
ister of controlled trials).
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Searching other resources
We will perform a search of the Family Health International Li-
brary (FHI 360) for all relevant trials, books and review articles.
FHI 360 is a nonprofit human development organization that
participates in research concerning various health issues including
contraception.
We will review the reference lists and contact authors of all iden-
tified studies for trials that could potentially be included in the
review. We will contact pharmaceutical companies that manufac-
ture condoms and request for trials carried out on male and female
condoms. We will contact experts in the field in order to find out
about possible unpublished trials. We will search conference pro-
ceedings of major conferences on gynaecology and reproductive
health.
We will not apply any language restriction and the search will be
carried out in order to identify published and unpublished studies.
Data collection and analysis
Selection of studies
Two review authors (NVM and CO) will independently assess
identified studies for inclusion. We will resolve any disagreement
through discussion and if required, wewill consult the third author
for a final decision.
Data extraction and management
We will design and test a data extraction form. For each included
study, the first two authors will extract the data independently
using the agreed form. We will then compare our forms and if
we do not agree on any aspect, we will discuss it and consult the
third author in order to find a consensus. We will enter data into
Revman 5.1.2 software (Revman 2011) and check for accuracy.
When information regarding any of the above is unclear, we will
attempt to contact authors of the original reports to provide further
details.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will resolve
any disagreement by discussion and by consulting the third author.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. This
is particularly relevant in this review because, due to differences
in presentation and use of the MCC and the FC, it is not possible
to blind the participants with respect to the interventions. The
lack of blinding may influence participant reported outcomes but
is not likely to affect objective outcomes like pregnancy or bio-
marker testing for semen exposure.
We will assess blinding separately for different outcomes or classes
of outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will assess blinding separately for dif-
ferent outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
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(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information is reported, or can be
supplied by the trial authors, we will re-include missing data in
the analyses which we undertake.
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation. We will consider studies with more that 20%
missing data as high risk of bias);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We will describe for each included study any important concerns
we have about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Cochrane
Handbook (Higgins 2011). With reference to (1) to (6) above,
we will assess the likely magnitude and direction of the bias and
whether we consider it is likely to impact on the findings. We will
explore the impact of the level of bias by undertaking sensitivity
analyses - see Sensitivity analysis.
Assessment of Quality of Evidence Across Studies
Wewill assess the quality of evidence using theGrading of Recom-
mendations Assessment, Development and Evaluation (GRADE)
approach (Guyatt 2008). We will dene the quality of evidence for
each outcome as the extent to which one can be condent that an
estimate of effect or association is close to the quantity of specic
interest (Higgins 2011). The quality rating across studies has four
levels: high, moderate, low or very low. Randomised controlled
trials are categorised as high quality but can be downgraded; sim-
ilarly, other types of controlled trials and observational studies are
categorised as low quality but can be upgraded. Factors that de-
crease the quality of evidence include limitations in design, indi-
rectness of evidence, unexplained heterogeneity or inconsistency
of results, imprecision of results, or high probability of publication
bias. Factors that can increase the quality level of a body of evi-
dence include having a large magnitude of effect, whether plausi-
ble confounding would reduce a demonstrated effect, and if there
is a dose-response gradient.
Measures of treatment effect
For dichotomous outcomes, we will present results as summary
risk ratio with 95% confidence intervals.
For continuous outcomes, we will use the mean difference if out-
comes aremeasured in the sameway between trials.We will use the
standardised mean difference when combining trials that measure
the same outcome using different methods.
Unit of analysis issues
Culster-randomised trials
Wewill include cluster-randomised trials in the analyses alongwith
individually randomised trials. We will adjust their sample sizes
using the methods described in the Handbook using an estimate
of the intra cluster correlation co-efficient (ICC) derived from
the trial (if possible), from a similar trial or from a study of a
similar population. If we use ICCs from other sources, we will
report this and conduct sensitivity analyses to investigate the effect
of variation in the ICC. If we identify both cluster-randomised
trials and individually-randomised trials, we plan to synthesise the
relevant information. We will consider it reasonable to combine
the results from both if there is little heterogeneity between the
study designs and the interactionbetween the effect of intervention
and the choice of randomisation unit is considered to be unlikely.
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Wewill also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis.
For all outcomes, we will carry out analyses, as far as possible,
on an intention-to-treat basis, i.e. we will attempt to include all
participants randomised to each group in the analyses, and all
participants will be analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each trial
will be the number randomised minus any participants whose
outcomes are known to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We will regard heterogeneity as
substantial if I² is greater than 30% and either T² is greater than
zero, or there is a low P value (less than 0.10) in the Chi² test for
heterogeneity.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis we will in-
vestigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually, and use for-
mal tests for funnel plot asymmetry. For continuous outcomes
we will use the test proposed by Egger (Egger 1997), and for di-
chotomous outcomes we will use the test proposed by Harbord
(Harbord 2006). If asymmetry is detected in any of these tests or
is suggested by a visual assessment, we will perform exploratory
analyses to investigate it.
Data synthesis
We will carry out statistical analysis using Revman 5.1.2 software
(Revman 2011). We will use fixed-effect meta-analysis for com-
bining data where it is reasonable to assume that studies are esti-
mating the same underlying treatment effect: i.e. where trials are
examining the same intervention, and the trials’ populations and
methods are judged sufficiently similar. If there is clinical hetero-
geneity sufficient to expect that the underlying treatment effects
differ between trials, or if substantial statistical heterogeneity is
detected, we will use random-effects meta-analysis to produce an
overall summary if an average treatment effect across trials is con-
sidered clinically meaningful. The random-effects summary will
be treated as the average range of possible treatment effects and
we will discuss the clinical implications of treatment effects differ-
ing between trials. If the average treatment effect is not clinically
meaningful we will not combine trials.
If we use random-effects analyses, the results will be presented as
the average treatment effect with 95% confidence intervals, and
the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
We intend to carry out the following subgroup analysis.
1) Exclusive male or female condom use versus male or female
condom use in association with another contraceptive method.
2) Male condom only or female condom only versus male and
female condom used concomitantly.
3) Various types of female condoms.
If we identify substantial heterogeneity, we will investigate it us-
ing subgroup analyses and sensitivity analyses. We will consider
whether an overall summary is meaningful and use random-effects
analysis to produce it.
For fixed-effect inverse variance meta-analyses we will assess dif-
ferences between subgroups by interaction tests. For random-ef-
fects and fixed-effect meta-analyses using methods other than in-
verse variance, we will assess differences between subgroups by in-
spection of the subgroups’ confidence intervals; non-overlapping
confidence intervals indicate a statistically significant difference in
treatment effect between the subgroups.
Sensitivity analysis
Sensitivity analysis will be carried out to explore the effect of trial
quality, including studies assessed as having adequate controls in
place for the prevention of potential bias.
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